{"id":"W2598916155","doi":"10.1200/jco.2004.22.90140.2622","title":"ARH460–16-2: a therapeutic monoclonal antibody targeting CD44 in Her2/neu negative breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Immunohistochemistry; CD44; Medicine; Breast cancer; Monoclonal antibody; Epitope; Cancer; Antigen; Cancer research; HER2/neu; Antibody; Pathology; Internal medicine; Immunology; Biology; Cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003762146,0.0003155332,0.0002115989,0.0004840661,0.0001547163,0.0002327283,0.0002761282,0.0004643155,0.002790115],"category_scores_gemma":[0.0001327726,0.0001314017,0.000152902,0.0002442114,0.0001456587,0.0001809289,0.0001741141,0.0003803995,0.001051726],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000262804,"about_ca_system_score_gemma":0.0001937162,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002146347,"about_ca_topic_score_gemma":0.0003606509,"domain_scores_codex":[0.9998404,0.00003256132,0.00001227567,0.00002758372,0.00004811297,0.00003901408],"domain_scores_gemma":[0.9999298,0.000009226461,0.00001481056,0.000007002754,0.00001167377,0.0000275321],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.0008854338,0.0005268649,0.004311257,0.0001710007,0.0000322497,0.0003527358,0.00002524594,0.0003434376,0.9570103,0.0001869357,0.001383197,0.03477126],"study_design_scores_gemma":[0.0006248417,0.00725595,0.05374348,0.00005808348,0.0001385412,0.0132735,0.00003704662,0.004675822,0.8821608,0.0001972137,0.03780937,0.00002538617],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781095,0.01138137,0.002777371,0.0003527662,0.0001128891,0.0001351639,0.0002900467,0.0001658883,0.006675073],"genre_scores_gemma":[0.9849169,0.0044009,0.004667552,0.0002066319,0.00009985052,0.00007494552,0.0007514523,0.00001667925,0.004865183],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002790115,"threshold_uncertainty_score":0.009333909,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1838038878909585,"score_gpt":0.5762637421299914,"score_spread":0.392459854239033,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}